Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

INTRODUCTION: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses. METHODS: Enrolled patients had ALK...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Thorac Oncol
Hlavní autoři: Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, Petris, Luigi De, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C., Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Zeaiter, Ali, Shaw, Alice T.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6886236/
https://ncbi.nlm.nih.gov/pubmed/28689043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2017.06.070
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky